Coinfection

Community Leaders, HIV Doctors Oppose Hepatitis C Treatment Barriers

A coalition of hepatitis C advocacy organizations and medical providers has issued an open letter to the Secretary of Health and Human Services calling for an end to restrictions on access to hepatitis C treatment by private insurers and public payers seeking to avoid the cost of newly approved direct-acting antivirals. HIV medical providers also called for reducing barriers to treatment, including restrictions on which medical specialists may treat people with hepatitis C.

alt

Read more:

Coverage of the Interscience Conference on Antimicrobial Agents and Chemotherapy

HIVandHepatitis.com coverage of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014), September 5-9, in Washington, DC.

Conference highlights include experimental antiretroviral therapies for HIV, interferon-free treatment for hepatitis C, and news about other infectious diseases including tuberculosis, HPV, influenza, and Ebola virus.

Full listing of coverage by topic

ICAAC 2014 website

9/8/14

alt

AIDS 2014: AbbVie 3D Regimen Cures Most Genotype 1 HIV/HCV Coinfected Patients

An all-oral regimen of 3 direct-acting antivirals plus ribavirin taken for 12 weeks demonstrated a sustained virological response rate of 94% for people coinfected with HIV and genotype 1 hepatitis C in the TURQUOISE-I study, according to a late-breaking report at the 20th International AIDS Conference (AIDS 2014) this week in Melbourne, Australia.

alt

Read more:

ICAAC 2014: AbbVie 3D Combination Works Well for People with HIV/HCV Coinfection

An all-oral regimen of 3 direct-acting antivirals plus ribavirin taken for 12 weeks led to sustained virological response in 94% of HIV positive people with mostly genotype 1a hepatitis C coinfection in the TURQUOISE-I study, according to data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC.

alt

Read more:

AIDS 2014: Sofosbuvir + Ribavirin Cures More Than 80% of HIV/HCV Coinfected People

An interferon-free regimen of sofosbuvir (Sovaldi) plus ribavirin for 24 weeks led to sustained virological response in 84% to 89% of HIV positive chronic hepatitis C patients with HCV genotypes 1, 2, 3, or 4, according to results from the PHOTON-2 study presented at the 20th International AIDS Conference in Melbourne, Australia. Cure rates were lower, however, for genotype 1a patients with liver cirrhosis.

alt

Read more:

Coverage of the 2014 International AIDS Conference

HIVandHepatitis.com coverage of the 20th International AIDS Conference (AIDS 2014), July 20-25, in Melbourne, Australia.

Conference highlights include biomedical HIV prevention (PrEP and treatment-as-prevention), HIV cure research, interferon-free therapy for hepatitis C and HIV/HCV coinfection, access to treatment, and fighting stigma and criminalization of key affected populations.

Full listing by topic

AIDS 2014 website

7/25/14

alt

Studies Look at Hepatitis C Care Cascade and Healthcare Utilization

Half of people with hepatitis C in the U.S. are aware of their infection, but fewer than 10% have been successfully treated and achieved sustained virological response (SVR), according to a meta-analysis published July 2 in the open-access journal PLoS ONE. Despite these gaps in testing, care, and treatment, hepatitis C accounts for a substantial share of healthcare utilization, especially among baby boomers, a related study found.

alt

Read more:

AIDS 2014: HIV/HCV Coinfected Have High Cure Rates with Interferon-free Hep C Combos

Two studies presented at the 20thInternational AIDS Conference this week in Melbourne showed that all-oral regimens of direct-acting antiviral agents for hepatitis C are safe and effective for HIV positive people. Both regimens demonstrated sustained virological response rates similar to those seen in people with HCV alone.

-- Sofosbuvir + Ribavirin Cures More Than 80% of HIV/HCV Coinfected People

-- AbbVie 3D Regimen Cures Most Genotype 1 HIV/HCV Coinfected Patients

alt

Read more:

ASCO: HCV Reactivation, Brain Involvement Do Not Worsen Lymphoma Survival for People with HIV

Reactivation of hepatitis C was common among HIV positive people with lymphoma, but did not appear to lead to worse outcomes or decreased survival, according to a study presented at the 50th American Society of Clinical Oncology (ASCO) meeting this week in Chicago. A related study found that having central nervous system involvement at the time of diagnosis did not decrease survival of people with AIDS-related lymphoma.

alt

Read more: